Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients
Passiglia, F., Perez, A., Listi', A., Castiglia, M., Musso, E., Ancona, C., et al. (2017). Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab. In Annals of Oncology 2017 [10.1093/annonc/mdx089].
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab
PASSIGLIA, Francesco;Perez, Alessandro;LISTI', Angela;CASTIGLIA, Marta;MUSSO, Emmanuela;ANCONA, Chiara;RIZZO, Sergio;RUSSO, Antonio
2017-01-01
Abstract
Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients
| File | Dimensione | Formato | |
|---|---|---|---|
|
Abstract_ELCC17,Ginevra.pdf
accesso aperto
Dimensione
2.07 MB
Formato
Adobe PDF
|
2.07 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
